Specialist Cohort Event Monitoring (SCEM) Studies

SCEM studies allow for the collection of exposure and outcome data within secondary care settings not possible in PEM and M-PEM studies. SCEM captures data on patients who may be more complex in terms of underlying disease, co-morbidities, and concomitant medications, and therefore at higher risk than those normally captured through prescription event monitoring methodologies. Further details about SCEM methodology and the differences between PEM and M-PEM can be found here.

Our SCEM methodology for studies in secondary care is explained in this short video:

 

The DSRU has established a number of SCEM studies to date over a range of therapeutic areas, including:

  • The completion of “OASIS”, a SCEM study in mental health secondary care examining the short-term safety and use of a newly licensed extended-release antipsychotic, using the immediate release formulationas a comparator group.
  • Ongoing recruitment to “OBSERVA”, a SCEM study within mental health secondary care examining the short-term safety and use of a newly licensed sublingual antipsychotic with particular emphasis on use and safety surrounding the sublingual administration.
  • Ongoing recruitment to “ROSE”, a SCEM study to monitor the short-term safety and utilisation of a novel oral anticoagulant by specialists in secondary care.
  • Further SCEM studies are in the pipeline.